russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLCrussjcardiol-1238Research ArticleПЕРЕДОВАЯ СТАТЬЯИНГИБИТОР If-КАНАЛОВ ИВАБРАДИН В ЛЕЧЕНИИ БОЛЬНЫХ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ: ВРЕМЯ ДЕБАТОВ ПРОШЛО, ПОРА ДЕЙСТВОВАТЬIF CHANNEL INHIBITOR IVABRADINE AND CHRONIC HEART FAILURE MANAGEMENT: FROM DISCUSSION TO ACTIONЛопатинЮ. М.LopatinYu. M.

заведующий кафедрой кардиологии ФУВ ВГМУ, заведующий отделом ВОКЦ

prof_lopatin@mail.ruФУВ Волгоградский государственный медицинский университет, Волгоградский областной кардиологический центр, ВолгоградРоссияVolgograd State Medical University, Volgograd Region Cardiology Centre, VolgogradRussian Federation20122808201204611Copyright © Лопатин Ю.М., 20122012Лопатин Ю.М.Lopatin Y.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/1238

Статья посвящена результатам рандомизированного клинического испытания SHIFT, которое определило начало дискуссии о выборе оптимальной тактики пульс-урежающей терапии у больных с хронической сердечной недостаточностью. Обсуждаются преимущества включения в схему лечения больных с хронической сердечной недостаточностью ингибитора If-каналов ивабрадина, а также позиция препарата в современных рекомендациях по ведению данной категории пациентов.

 

 

 

 

The paper is focused on the results of a randomised clinical trial SHIFT, which started the discussion about the choice of optimal heart rate-lowering therapy in patients with chronic heart failure (CHF). The author summarizes the benefits of adding an If channel inhibitor ivabradine to the standard CHF therapy and presents the place of this medication in the modern clinical guidelines on CHF management.

хроническая сердечная недостаточностьбета-блокаторыингибитор If-каналов ивабрадинchronic heart failurebeta-blockersIf channel inhibitor ivabradineReferencesSwedberg K., Komajda M., Bohm M. et al. on behalf of the SHIFT investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. Lancet. 2010; 376: 875–85.Swedberg K., Komajda M., Bohm M. et al. on behalf of the SHIFT investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. Lancet. 2010; 376: 875–85.Diaz A., Bourassa M. G., Guertin M. C. et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur. Heart J. 2005; 26: 967–74.Diaz A., Bourassa M. G., Guertin M. C. et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur. Heart J. 2005; 26: 967–74.Wilhelmsen L., Berglund G., Elmfeldt D. et al. The multifactor primary prevention trial in Goteborg, Sweden. Eur. Heart J. 1986; 7: 279–88.Wilhelmsen L., Berglund G., Elmfeldt D. et al. The multifactor primary prevention trial in Goteborg, Sweden. Eur. Heart J. 1986; 7: 279–88.Fox K., Ford I., Steg P. G. et al. on behalf of the BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular dysfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trial. Lancet. 2008; 372: 817–21.Fox K., Ford I., Steg P. G. et al. on behalf of the BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular dysfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trial. Lancet. 2008; 372: 817–21.Consensus of Heart Failure Experts Society. Results of SHIFT trial and recommendations on including Koraksan into treatment scheme of patients with CHF and sinus rhythm. Serdechnaya nedostatochnost 2011; 12, 2 (64): 117–118. Russian (Согласованное мнение экспертов Общества специалистов по сердечной недостаточности. Результаты исследования SHIFT и рекомендации по включению Кораксана в схему лечения пациентов с ХСН и синусовым ритмом. Журнал Сердечная Недостаточность 2011; 12, 2 (64): 117–118).Consensus of Heart Failure Experts Society. Results of SHIFT trial and recommendations on including Koraksan into treatment scheme of patients with CHF and sinus rhythm. Serdechnaya nedostatochnost 2011; 12, 2 (64): 117–118. Russian (Согласованное мнение экспертов Общества специалистов по сердечной недостаточности. Результаты исследования SHIFT и рекомендации по включению Кораксана в схему лечения пациентов с ХСН и синусовым ритмом. Журнал Сердечная Недостаточность 2011; 12, 2 (64): 117–118).Ekman I., Chassany O., Komajda M. et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur. Heart J. doi:10.1093/eurheartj/ehr343.Ekman I., Chassany O., Komajda M. et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur. Heart J. doi:10.1093/eurheartj/ehr343.Tardif J.-C., O’Meara E., Komajda M. et al. on behalf of the SHIFT Investigators. Effects of selective heart rate reduction with ivabradine on left ventricular remodeling and function: results from the SHIFT echocardiography substudy. Eur. Heart J. doi:10.1093/eurheartj/ehr311.Tardif J.-C., O’Meara E., Komajda M. et al. on behalf of the SHIFT Investigators. Effects of selective heart rate reduction with ivabradine on left ventricular remodeling and function: results from the SHIFT echocardiography substudy. Eur. Heart J. doi:10.1093/eurheartj/ehr311.Bohm M., Borer J., Ford I. et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin. Res. Cardiol. 2012; DOI 10.1007/s00392–012–0467–8Bohm M., Borer J., Ford I. et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin. Res. Cardiol. 2012; DOI 10.1007/s00392–012–0467–8National recommendations of VNOK and SSHF on the diagnostics and treatment of chronic heart failure (third review). Serdechnaya nedostatochnost 2010; 11, 1 (57): 3–62. Russian (Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность 2010; 11, 1 (57): 3–62).National recommendations of VNOK and SSHF on the diagnostics and treatment of chronic heart failure (third review). Serdechnaya nedostatochnost 2010; 11, 1 (57): 3–62. Russian (Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность 2010; 11, 1 (57): 3–62).ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur. Heart J. 2012; doi:10.1093/eurheartj/ehs104.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur. Heart J. 2012; doi:10.1093/eurheartj/ehs104.Sarraf M., Francis G. S. It Is All About Heart Rate. Or Is It? JACC 2012; 59: 1946–47.Sarraf M., Francis G. S. It Is All About Heart Rate. Or Is It? JACC 2012; 59: 1946–47.Teerlink J. R. Ivabradine in heart failure – no paradigm SHIFT… yet. Lancet 2010; 376: 847–49.Teerlink J. R. Ivabradine in heart failure – no paradigm SHIFT… yet. Lancet 2010; 376: 847–49.Ageev F. T. The SHIFT Study: a Shift in a Correct Direction? Cardiology 2012; 1, 83–85. Russian (Агеев Ф. Т. Исследование SHIFT: сдвиг в правильном направлении? Кардиология 2012; 1: 83–85).Ageev F. T. The SHIFT Study: a Shift in a Correct Direction? Cardiology 2012; 1, 83–85. Russian (Агеев Ф. Т. Исследование SHIFT: сдвиг в правильном направлении? Кардиология 2012; 1: 83–85).CIBIS-II Investigators and Committies. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomized trial. Lancet 1999; 353: 9–13.CIBIS-II Investigators and Committies. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomized trial. Lancet 1999; 353: 9–13.MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001–7.MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001–7.Packer M., Coats A. J. S., Fowler M. B. et al. for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 2001; 344: 1651–58.Packer M., Coats A. J. S., Fowler M. B. et al. for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 2001; 344: 1651–58.Komajda M., Follath F., Swedberg K. et al. The EuroHeart Failure Survey programme – a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur. Heart J. 2003; 24: 464–74.Komajda M., Follath F., Swedberg K. et al. The EuroHeart Failure Survey programme – a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur. Heart J. 2003; 24: 464–74.de Groote P., Isnard R., Assyag P. et al. Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur. J. Heart Fail.2007; 9: 1205–11.de Groote P., Isnard R., Assyag P. et al. Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur. J. Heart Fail.2007; 9: 1205–11.Dahlstrom U., Hakansson J., Swedberg K. et al. Adequacy of diagnosis and treatment of chronic heart failure in primary health care in Sweden. Eur. J. Heart Fail.2009; 11: 92–98.Dahlstrom U., Hakansson J., Swedberg K. et al. Adequacy of diagnosis and treatment of chronic heart failure in primary health care in Sweden. Eur. J. Heart Fail.2009; 11: 92–98.Maggioni A. P., Dahlstrom U., Filippatos G., et al. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur. J. Heart. Fail. 2010; 12:1076–84.Maggioni A. P., Dahlstrom U., Filippatos G., et al. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur. J. Heart. Fail. 2010; 12:1076–84.Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur. Heart J. 2005; 26: 1115–40.Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur. Heart J. 2005; 26: 1115–40.

The authors declare that there are no conflicts of interest present.